Please use this identifier to cite or link to this item: https://doi.org/10.1002/med.20254
DC FieldValue
dc.titleThe A3 adenosine receptor as multifaceted therapeutic target: Pharmacology, medicinal chemistry, and in silico approaches
dc.contributor.authorCheong, S.L.
dc.contributor.authorFederico, S.
dc.contributor.authorVenkatesan, G.
dc.contributor.authorMandel, A.L.
dc.contributor.authorShao, Y.-M.
dc.contributor.authorMoro, S.
dc.contributor.authorSpalluto, G.
dc.contributor.authorPastorin, G.
dc.date.accessioned2014-12-12T07:52:07Z
dc.date.available2014-12-12T07:52:07Z
dc.date.issued2013-03
dc.identifier.citationCheong, S.L., Federico, S., Venkatesan, G., Mandel, A.L., Shao, Y.-M., Moro, S., Spalluto, G., Pastorin, G. (2013-03). The A3 adenosine receptor as multifaceted therapeutic target: Pharmacology, medicinal chemistry, and in silico approaches. Medicinal Research Reviews 33 (2) : 235-335. ScholarBank@NUS Repository. https://doi.org/10.1002/med.20254
dc.identifier.issn01986325
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/116621
dc.description.abstractAdenosine is an ubiquitous local modulator that regulates various physiological and pathological functions by stimulating four membrane receptors, namely A1, A2A, A2B, and A3. Among these G protein-coupled receptors, the A3 subtype is found mainly in the lung, liver, heart, eyes, and brain in our body. It has been associated with cerebroprotection and cardioprotection, as well as modulation of cellular growth upon its selective activation. On the other hand, its inhibition by selective antagonists has been reported to be potentially useful in the treatment of pathological conditions including glaucoma, inflammatory diseases, and cancer. In this review, we focused on the pharmacology and the therapeutic implications of the human (h)A3 adenosine receptor (AR), together with an overview on the progress of hA3AR agonists, antagonists, allosteric modulators, and radioligands, as well as on the recent advances pertaining to the computational approaches (e.g., quantitative structure-activity relationships, homology modeling, molecular docking, and molecular dynamics simulations) applied to the modeling of hA3AR and drug design. © 2011 Wiley Periodicals, Inc.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1002/med.20254
dc.sourceScopus
dc.subjectAgonist
dc.subjectAllosteric modulator
dc.subjectAntagonist
dc.subjectHuman A3 adenosine receptor
dc.subjectMolecular modeling
dc.subjectPharmacology
dc.subjectTherapeutic potential
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.contributor.departmentNUS NANOSCIENCE & NANOTECH INITIATIVE
dc.description.doi10.1002/med.20254
dc.description.sourcetitleMedicinal Research Reviews
dc.description.volume33
dc.description.issue2
dc.description.page235-335
dc.description.codenMRRED
dc.identifier.isiut000315102500001
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

41
checked on Apr 20, 2021

WEB OF SCIENCETM
Citations

38
checked on Apr 20, 2021

Page view(s)

74
checked on Apr 10, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.